Breaking News Instant updates and real-time market news.

PANW

Palo Alto Networks

$227.02

(0.00%)

, SLV

iShares Silver Trust

$15.91

(0.00%)

09:40
12/02/19
12/02
09:40
12/02/19
09:40

Unusually active option classes on open December 2nd

Unusual total active option classes on open include: Palo Alto Networks (PANW), iShares Silver Trust (SLV), iShares 20 Year Treasury Bond ETF (TLT), Home Depot (HD), Visa (V), Bristol Myers Squibb (BMY), ProShares UltraPro QQQ (TQQQ), Beyond Meat (BYND), Salesforce (CRM), and Intel (INTC).

PANW

Palo Alto Networks

$227.02

(0.00%)

SLV

iShares Silver Trust

$15.91

(0.00%)

TLT

iShares 20+ Year Treasury Bond Fund

$140.43

(0.00%)

HD

Home Depot

$220.59

(0.00%)

V

Visa

$184.51

(0.00%)

BMY

Bristol-Myers

$57.03

(0.00%)

TQQQ

ProShares UltraPro QQQ

$77.70

(0.00%)

BYND

Beyond Meat

$82.86

(0.00%)

CRM

Salesforce

$162.90

(0.00%)

INTC

Intel

$58.06

(0.00%)

  • 02

    Dec

  • 02

    Dec

  • 03

    Dec

  • 07

    Dec

  • 08

    Dec

  • 09

    Dec

  • 09

    Dec

  • 10

    Dec

  • 11

    Dec

  • 11

    Dec

  • 16

    Dec

  • 23

    Jan

  • 25

    Feb

PANW Palo Alto Networks
$227.02

(0.00%)

11/26/19
WEDB
11/26/19
NO CHANGE
Target $275
WEDB
Outperform
Wedbush still 'firmly bullish' on Palo Alto Networks despite product miss
Wedbush analyst Daniel Ives says Palo Alto Networks reported "mixed" October quarter results last night as the company beat the Street's sales and billings estimates while delivering "weak" product and cash flow numbers. The analyst, however, is "not overly alarmed" by the product miss and remains "firmly bullish" on the company and risk/reward for the next year. He keeps an Outperform rating on Palo Alto Networks with a $275 price target.
11/26/19
DADA
11/26/19
NO CHANGE
Target $245
DADA
Neutral
Palo Alto Networks price target lowered to $245 from $260 at DA Davidson
DA Davidson analyst Andrew Nowinski lowered his price target on Palo Alto Networks to $245 and kept his Neutral rating after its mixed Q1 results, saying the company's strong next-gen billings growth of 217% was overshadowed by the decline in product revenue. The analyst adds that while the management has slightly raised its billings guidance by $10M at the midpoint, the quarter support his thesis that the next-gen product component of overall sales is still too small while the core firewall solutions are decelerating.
11/26/19
JPMS
11/26/19
NO CHANGE
Target $284
JPMS
Overweight
Palo Alto Networks price target lowered to $284 from $300 at JPMorgan
JPMorgan analyst Sterling Auty lowered his price target for Palo Alto Networks to $284 from $300 citing the company's "self-inflicted" product issues in fiscal Q1. The quarter will leave investors "feeling uneasy about the health of network security, demand for cyber security, and where we are in the shift to the cloud," Auty tells investors in a post-earnings research note. He believes the product revenue issues are a result of overstimulating focus on cloud security products through the use of temporary sales incentives. Auty keeps an Overweight rating on Palo Alto.
11/26/19
OPCO
11/26/19
NO CHANGE
Target $275
OPCO
Outperform
Palo Alto Networks price target lowered to $275 from $285 at Oppenheimer
Oppenheimer analyst Shaul Eyal lowered his price target for Palo Alto Networks to $275 from $285 following the company's "mixed" Q1 results. The analyst, however, believes the company's long-term outlook is intact and he maintains an Outperform rating on the name.
SLV iShares Silver Trust
$15.91

(0.00%)

TLT iShares 20+ Year Treasury Bond Fund
$140.43

(0.00%)

HD Home Depot
$220.59

(0.00%)

11/19/19
BARD
11/19/19
NO CHANGE
Target $245
BARD
Outperform
Home Depot price target raised to $245 from $230 at Baird
Baird analyst Peter Benedict said Home Depot's softer than expected Q3 comp growth and reduced FY19 sales plan "drove a healthy pullback in shares today," but its underlying trends appear supportive of sequentially improved same-store sales and its implied Q4 guidance appears conservative. The analyst, who is "inclined to patiently accumulate shares," keeps an Outperform rating on Home Depot with an increased price target of $245, up from $230.
11/20/19
LOOP
11/20/19
NO CHANGE
Target $205
LOOP
Hold
Home Depot price target raised to $205 from $200 at Loop Capital
Loop Capital analyst Laura Champine raised her price target on Home Depot to $205, noting that while the stock fell over 5% yesterday after its Q3 top-line miss and the second consecutive quarter of lower revenue projections, she sees "more bullish" long-term gross margins given the company's pricing and purchasing power. The analyst still keeps her Hold rating on Home Depot, stating that its valuation remains "somewhat rich" at 21-times her expected FY20 earnings and 14-times on enterprise value to expected EBITDA basis.
11/21/19
RHCO
11/21/19
NO CHANGE
Target $225
RHCO
Hold
Home Depot price target raised to $225 from $208 at SunTrust
SunTrust analyst Keith Hughes raised his price target on Home Depot (HD) to $225 after its Q3 results, noting that while the stock was down from the miss in comps and another cut in FY19 same-store sales view to 3.5% from 4%, the company still outperformed the 3% U.S. comps print at Lowe's (LOW). The analyst believes that Home Depot is having a "share gaining year" and expects both chains to see improved results next year, even though he is keeping his Hold rating on the view that Q4 SSS estimates are still "somewhat high".
11/22/19
RHCO
11/22/19
NO CHANGE
Target $135
RHCO
Buy
Lowe's price target raised to $135 from $120 at SunTrust
SunTrust analyst Keith Hughes raised his price target on Lowe's (LOW) to $135 and kept his Buy rating after its Q3 earnings beat and raised FY19 guidance. The analyst notes that the company's comp growth is still below that of Home Depot (HD), but unlike the latter, the management did not cut its SSS outlook for the year. Hughes still sees Lowe's progressing in its turnaround, but notes that the trend has been "uneven" and increasing online sales with take the company "some time to realize".
V Visa
$184.51

(0.00%)

10/28/19
BMOC
10/28/19
NO CHANGE
Target $239
BMOC
Outperform
Visa price target raised to $239 from $231 at BMO Capital
BMO Capital analyst James Fotheringham raised his price target on Visa to $239 and kept his Outperform rating after its Q4 earnings beat and encouraging FY20 guidance driven by improved incentives, reduced operating costs, and lower assumed tax rate. The analyst further cites "encouraging" FY20 guidance, adding that the stock remains his top recommendation among U.S.financial technology, large-cap banks, specialty lenders, and asset manager companies. Fotheringham also raises his FY21 EPS view on Visa by 6c to $7.41.
10/31/19
BMOC
10/31/19
NO CHANGE
Target $348
BMOC
Outperform
MasterCard price target raised to $348 from $328 at BMO Capital
BMO Capital analyst James Fotheringham raised his price target on MasterCard (MA) to $348 and kept his Outperform rating after its "broad-based" Q3 earnings beat. The analyst believes that the company can grow its revenue faster than previously expected given its exposure to fast-growing international markets, B2B payment flows, and cross-border volume, offsetting its indicated higher marketing spend. Fotheringham prefers Visa (V) to MasterCard however due to a relative valuation discount.
11/04/19
BMOC
11/04/19
NO CHANGE
Target $186
BMOC
Market Perform
Global Payments price target raised to $186 from $162 at BMO Capital
BMO Capital analyst James Fotheringham raised his price target on Global Payments (GPN) to $186 after its Q3 revenue beat driven by better margin and stronger growth in Europe in spite of the Brexit related concerns. The analyst adds that while the company also provided higher synergy targets, he is keeping his Market Perform rating on the stock with preference toward Visa (V), MasterCard (MA), and PayPal (PYPL) due to more attractive valuations.
11/13/19
11/13/19
NO CHANGE

Baird says FTC probe not overly material to Visa, MasterCard
Baird analyst David Koning noted that a Bloomberg report said the FTC will look into Visa (VA) and Mastercard (MA) regarding debit card transaction routing, but the analyst doesn't view this as overly material to the companies, as U.S. PIN debit is "only about 2% of revenue... as these are much lower-priced transactions than average." The analyst estimated that the companies earn "maybe 2c-3c on a PIN debit transaction compared with 7c-8c on a signature debit transaction."
BMY Bristol-Myers
$57.03

(0.00%)

11/27/19
GABE
11/27/19
INITIATION
GABE
Buy
Bristol-Myers Squibb CVR initiated with a Buy at Gabelli
Gabelli analyst Kevin Kedra initiated coverage of Bristol-Myers Squibb CVR (BMY-R) with a Buy rating and private market value estimate of $3.50. CVR holders will receive a $9.00 payout if all three of the FDA approval milestones are met, Kedra tells investors in a research note. The analyst sees an 80% probability for the ozanimod milestone, an 86% probability for JCAR017, and 68% probability for bb2121. He recommends the Bristol-Myers CVR as an attractive risk/reward opportunity with multiple near-term catalysts.
11/27/19
11/27/19
INITIATION

Fly Intel: Top analyst initiations
Catch up on today's top analyst initiations with this list compiled by The Fly: 1. Vonage (VG) initiated with a Neutral at JPMorgan. 2. Bristol-Myers Squibb CVR (BMY-R, BMY) initiated with a Buy at Gabelli. 3. Novus Therapeutics (NVUS) initiated with a Buy at H.C. Wainwright. 4. KushCo Holdings (KSHB) initiated with a Buy at Jefferies. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
11/25/19
MZHO
11/25/19
INITIATION
Target $3.14
MZHO
Buy
Bristol-Myers Squibb CVR initiated with a Buy at Mizuho
Mizuho analyst Salim Syed initiated coverage of Bristol-Myers Squibb CVR with a Buy rating and $3.14 price target.
11/22/19
MSCO
11/22/19
INITIATION
Target $60
MSCO
Equal Weight
Bristol-Myers resumed with an Equal Weight at Morgan Stanley
Morgan Stanley analyst David Risinger resumed coverage of Bristol-Myers with an Equal Weight rating and $60 price target following the closing of the acquisition of Celgene. The deal makes Bristol "a top global cancer company" and he sees solid near-term growth, but he also believes that the combined company faces erosion over the longer-term for key franchises and he prefers to wait for further pipeline developments, Risinger tells investors.
TQQQ ProShares UltraPro QQQ
$77.70

(0.00%)

BYND Beyond Meat
$82.86

(0.00%)

11/08/19
11/08/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Beyond Meat (BYND) initiated with a Neutral at UBS. 2. NortonLifeLock (NLOK) resumed with a Sector Perform at RBC Capital. 3. Manitex (MNTX) resumed with a Buy at Roth Capital. 4. Oneok (OKE) initiated with a Buy at Tudor Pickering. 5. II-VI (IIVI) initiated with an Outperform at Raymond James. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
11/14/19
BREN
11/14/19
INITIATION
Target $100
BREN
Buy
Beyond Meat initiated with Buy rating, $100 price target at Berenberg
Berenberg analyst Donald McLee initiated coverage of Beyond Meat with a Buy rating and $100 price target. The stock closed Wednesday up 75c to $79.02. The plant-based meat category is in the early stages of a "second evolution," McLee tells investors in a research note. He believes its addressable market is expanding beyond the traditional vegan and vegetarian consumer, and expects this trajectory will continue "as major food manufacturers enter the space and the category matures." The analyst views Beyond Meat as among the best positioned to capitalist on the "burgeoning" plant-protein market.
11/14/19
BREN
11/14/19
INITIATION
Target $100
BREN
Buy
Berenberg bullish on plant-based meats, starts Beyond Meat at Buy
Berenberg analyst Donald McLee initiated coverage of three companies involved in the plant-based meat category, which he sees being in the early stages of "its second evolution" as modern plant-protein have progressed significantly toward replicating the experience of animal meat. He started Beyond Meat (BYND) with a Buy rating and $100 price target, identifying it as "the only public, pure-play plant-based meat company." He sees its advantages in innovation, brand awareness, distribution and portfolio making Beyond well-positioned to capture share, McLee tells investors. While he expects strong plant-based trend tailwinds to create a tide that lifts all boats, not all of the competitors in the space are created equal and McLee identifies Conagra's (CAG) Gardein Beyond Meat and Impossible Foods as the three best-positioned plant-based brands.
11/15/19
WBLR
11/15/19
NO CHANGE
WBLR
Outperform
William Blair stays positive on Beyond Meat after management meetings
After hosting investors at Beyond Meat headquarters with CEO Ethan Brown and CFO Mark Nelson, William Blair analyst Jon Andersen says management reaffirmed the company's "fundamental underpinnings," including a large addressable market, positive consumer response to the brand and product line, and strategic partnerships with restaurants and retailers. The analyst believes demand for plant-based meat could eclipse plant-based milk levels given the "salient" health concerns regarding consumption of animal meat and the "compelling" environmental benefits associated with the removal of the animal from the protein production chain. While valuation could limit stock price appreciation in the near term, Andersen believes Beyond Meat shareholders "should be rewarded long term." The analyst keeps an Outperform rating on the shares.
CRM Salesforce
$162.90

(0.00%)

11/21/19
RBCM
11/21/19
NO CHANGE
Target $200
RBCM
Outperform
Salesforce preliminary FY20-21 guidance likely conservative, says RBC Capital
RBC Capital analyst Alex Zukin keeps his Outperform rating and $200 price target on Salesforce after attending the Dreamforce conference, saying the discussion makes him believe that its preliminary guidance is "conservative with potential to outperform the top and bottom line through FY20 and FY21." The analyst adds that CEO Benioff indicated that the company is entering a "digestion period" after its recent uptick in M&A. Zukin contends that Salesforce can grow its current remaining performance obligation, or cRPO by over 20%, and has many avenues to sustain that growth, even though some deceleration is "inevitable".
12/02/19
RBCM
12/02/19
NO CHANGE
Target $93
RBCM
Outperform
DocuSign price target raised to $93 from $80 at RBC Capital
RBC Capital analyst Alex Zukin raised his price target on DocuSign (DOCU) to $93 and kept his Outperform rating ahead of its Q3 results, saying his conversations with partners and management along with his analysis of financials suggest that the quarter should be "solid". The analyst sees the company benefiting from continued favorable trends seen in Q2, as its SpringCM product is performing ahead of expectations. Zukin adds that DocuSign is expanding relationships with ISV partners such as Salesforce (CRM).
11/21/19
BARD
11/21/19
NO CHANGE
Target $185
BARD
Outperform
Salesforce represents best opportunity in large-cap software, says Baird
Baird analyst Rob Oliver believes Salesforce represents the best investment opportunity in the large-cap software space. The analyst attended the annual Dreamforce analyst day where the company stressed gross margin expansion and said they would step back from M&A in the near-term while it works on integrating its recent acquisitions. Oliver reiterated his Outperform rating and $185 price target on Salesforce shares.
11/21/19
COWN
11/21/19
NO CHANGE
Target $195
COWN
Outperform
Salesforce price target raised to $195 from $185 at Cowen
Cowen analyst J. Derrick Wood raised his price target on Salesforce to $195 from $185 following its upbeat Analyst Day and raised 2020 revenue guidance. The analyst said management commentary on the macro-economy was constructive as digital transformation is an imperative for companies globally. Wood reiterated his Outperform rating on Salesforce shares.
INTC Intel
$58.06

(0.00%)

11/21/19
NORL
11/21/19
DOWNGRADE
Target $36
NORL
Market Perform
Northland downgrades AMD, says shares ahead of fundamentals after rally
Northland analyst Gus Richard downgraded AMD (AMD) to Market Perform from Outperform with an unchanged price target of $36. The chipmaker closed Wednesday up 86c to $45.86. AMD shares are now ahead of the company's fundamentals, Richard tells investors in a research note titled "Bull and Bears Make Money, Pigs Get Slaughtered." The analyst says that while the shares "are likely to melt up between now and the end of the year," he would not be chasing them. He expects profit taking in the new year and thinks 2020 will represent a "peak growth year" for AMD. Further, as AMD market share increases, incremental share gains "get much more difficult" due to Intel's (INTC) incumbency, contends Richard.
11/19/19
MZHO
11/19/19
NO CHANGE
Target $38
MZHO
Neutral
More Intel price cuts present challenge for AMD, says Mizuho
Mizuho analyst Vijay Rakesh's channel checks indicate that Intel (INTC) is cutting Cascade Lake pricing again, now to parity with Skylake, which he feels presents a challenge to AMD. He believes that with Skylake processor supply tight, Intel has dropped Cascade Lake pricing to parity with Skylake in some instances, which equates to an incremental 25%-30% discount. Intel is offering software support and aggressive pricing, which could position it to aggressively compete with AMD, Rakesh tells investors in a research note. Further, heading into year-end, the analyst expects U.S. hyperscale to slowdown seasonally with some potential weakness at China hyperscale. In addition, Rakesh raised his price target for Neutral-rated AMD (AMD) to $38 from $36 and for Buy-rated Intel (INTC) to $64 from $60 to reflect the recent expansion of semiconductor multiples.
12/02/19
BOFA
12/02/19
NO CHANGE
Target $70
BOFA
Buy
Intel price target raised to $70 from $65 at BofA/Merrill
BofA Merrill Lynch analyst Vivek Arya raised his price target on Intel shares to $70 from $65, noting that his 2020 pro-forma EPS estimate is 10% above consensus. He sees five reasons to stay positive on Intel, including the fact that 2019 will mark the second consecutive year of year-over-year sales growth outperforming core semis and he sees that trend repeating in 2020. The other four reasons to stay positive are Intel's continued opportunity to "right-size" its operating expenses; the company's "monster" buyback authorization; the expanding size of the "computing pie"; and what he views as a compelling valuation given the company's "highly strategic" U.S. assets. Arya keeps a Buy rating on Intel shares.
11/21/19
NEED
11/21/19
NO CHANGE
Target $45
NEED
Buy
Vicor Corporation price target raised to $45 from $42 at Needham
Needham analyst N. Quinn Bolton raised his price target on Vicor Corporation (VICR) to $45 and kept his Buy rating, saying the discussion at this week's SC19 Conference has made him "incrementally more positive" on the company's position as a leading supplier of 48V power solutions in the hyperscale data center and HPC markets. The analyst notes that the company appears to have secured design wins on NVIDIA's (NVDA) supercomputer instances as well as Intel's (INTC) Ponte Vecchio 7nm Xe GPU platform. Bolton also states that Vicor's 5-times enterprise value to expected 2021 sales multiple is largely in line with its analog/mixed-signal peer group.

TODAY'S FREE FLY STORIES

VCYT

Veracyte

$29.00

0.46 (1.61%)

09:36
12/11/19
12/11
09:36
12/11/19
09:36
Conference/Events
Veracyte management to meet with William Blair »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

  • 16

    Dec

09:34
12/11/19
12/11
09:34
12/11/19
09:34
Conference/Events
Senate Commerce, Science & Transportation Committee holds executive session »

The Committee holds an…

ROAD

Construction Partners

$16.72

-3.84 (-18.68%)

09:33
12/11/19
12/11
09:33
12/11/19
09:33
Recommendations
Construction Partners analyst commentary  »

Construction Partners…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TRUP

Trupanion

$33.89

0.02 (0.06%)

09:33
12/11/19
12/11
09:33
12/11/19
09:33
Conference/Events
Trupanion management to meet with Lake Street »

Meeting to be held in San…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

THTX

Theratechnologies

$3.05

-0.01 (-0.33%)

09:33
12/11/19
12/11
09:33
12/11/19
09:33
Upgrade
Theratechnologies rating change  »

Theratechnologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AKER

Akers Biosciences

$2.94

0.03 (1.03%)

09:32
12/11/19
12/11
09:32
12/11/19
09:32
Hot Stocks
Akers Biosciences regains compliance with Nasdaq listing standards »

Akers Biosciences…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Dec

SPB

Spectrum Brands

$61.63

-1.44 (-2.28%)

09:31
12/11/19
12/11
09:31
12/11/19
09:31
Conference/Events
Spectrum Brands management to meet with Oppenheimer »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

  • 13

    Dec

RMAX

RE/MAX Holdings

$39.09

0.24 (0.62%)

09:29
12/11/19
12/11
09:29
12/11/19
09:29
Conference/Events
RE/MAX Holdings management to meet with Craig-Hallum »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

PLPRF

Plus Products

$0.00

(0.00%)

09:28
12/11/19
12/11
09:28
12/11/19
09:28
Hot Stocks
Plus Products transitions to HERBL as primary California distribution partner »

Plus Products announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DIS

Disney

$146.12

-0.07 (-0.05%)

09:28
12/11/19
12/11
09:28
12/11/19
09:28
Periodicals
Disney+ eclipses 22M mobile downloads, CNBC reports »

Disney+ has been…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PNTG

The Pennant Group

$27.98

1.49 (5.62%)

09:28
12/11/19
12/11
09:28
12/11/19
09:28
Conference/Events
The Pennant Group management to meet with RBC Capital »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

HD

Home Depot

$215.84

-0.75 (-0.35%)

09:26
12/11/19
12/11
09:26
12/11/19
09:26
Recommendations
Home Depot analyst commentary  »

Home Depot price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

  • 25

    Feb

BIIB

Biogen

$297.05

1.58 (0.53%)

09:26
12/11/19
12/11
09:26
12/11/19
09:26
Conference/Events
SVB Leerink biotech analyst to hold analyst/industry conference call »

Biotech Analysts, along…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PJT

PJT Partners

$42.80

0.2 (0.47%)

09:25
12/11/19
12/11
09:25
12/11/19
09:25
Conference/Events
PJT Partners management to meet with JMP Securities »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

  • 26

    Feb

MRMD

Marimed

$0.00

(0.00%)

09:25
12/11/19
12/11
09:25
12/11/19
09:25
Hot Stocks
Marimed to open dispensary in Middleborough, Massachusetts »

MariMed received final…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

09:25
12/11/19
12/11
09:25
12/11/19
09:25
General news
FOMC resumed its 2-day meeting »

FOMC resumed its 2-day…

09:25
12/11/19
12/11
09:25
12/11/19
09:25
Conference/Events
JPMorgan life science tools analyst to hold an analyst/industry conference call »

Life Science Tools &…

TREE

LendingTree

$324.87

-12.55 (-3.72%)

09:25
12/11/19
12/11
09:25
12/11/19
09:25
Conference/Events
LendingTree to host analyst & investor day »

Analyst & Investor…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

PFG

Principal Financial

$53.26

(0.00%)

09:25
12/11/19
12/11
09:25
12/11/19
09:25
Conference/Events
Principal Financial to hold a conference call »

Conference call to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

FCEL

FuelCell

$0.53

0.014 (2.73%)

09:24
12/11/19
12/11
09:24
12/11/19
09:24
Initiation
FuelCell initiated  »

FuelCell reinstated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

  • 14

    Jan

PCTY

Paylocity

$120.35

-0.86 (-0.71%)

09:23
12/11/19
12/11
09:23
12/11/19
09:23
Conference/Events
Paylocity management to meet with JMP Securities »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

  • 13

    Dec

TYHT

Shineco

$1.00

0.0099 (1.00%)

09:21
12/11/19
12/11
09:21
12/11/19
09:21
Hot Stocks
Shineco signs $10M industry hemp fiber preliminary processing sales contract »

Shineco announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LLNW

Limelight Networks

$4.03

-0.245 (-5.73%)

09:21
12/11/19
12/11
09:21
12/11/19
09:21
Recommendations
Limelight Networks analyst commentary  »

Limelight Networks price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MTBC

MTBC

$4.26

-0.04 (-0.93%)

09:19
12/11/19
12/11
09:19
12/11/19
09:19
Hot Stocks
MTBC announces release of telemedicine solution »

MTBC announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

CONN

Conn's

$13.60

-6.91 (-33.69%)

09:18
12/11/19
12/11
09:18
12/11/19
09:18
Recommendations
Conn's analyst commentary  »

Conn's price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.